Multiple Myeloma Hub

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, provided an overview of B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM).

During this presentation, Schjesvold provides an overview of currently available BCMA-directed therapies, including antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Schjesvold outlines differences in mechanisms of action, regulatory approvals, treatment settings, and key efficacy and safety data across approved agents.

This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

Hosted on Acast. See acast.com/privacy for more information.

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). 

In this presentation, Popat discusses the importance of health-related QoL as a key clinical outcome in MM, particularly in the context of increasingly effective therapies. Popat emphasizes the need to balance efficacy and safety with QoL and outlines patient-, disease-, and treatment-related factors that influence QoL. Practical considerations, including treatment logistics, adverse events, and patient preferences, are also discussed, alongside approaches to assessing QoL and incorporating shared decision-making into clinical practice. 

This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. 

Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM).

The session covered mechanisms of resistance with BCMA-targeted therapies; the impact of prior exposure to BCMA-directed therapies; the main differences between BCMA-directed antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies in terms of access, logistics, and toxicity profiles; and how dosing schedules can be adapted to optimize efficacy while limiting toxicity.

This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Maria Victoria Mateos provided an overview of the potential future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment paradigm.

This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Gordon Cook, University of Leeds, UK, delivered a presentation covering real-world insights and clinical experience with BCMA-directed therapies.

In this presentation, Cook examined how populations enrolled in pivotal trials of BCMA-directed therapies compare with patients treated in routine clinical practice. Key differences were highlighted, including age, performance status, comorbidities, and prior treatment exposure. Cook presented data for bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, focusing on efficacy and safety outcomes in real-world populations as well as the impact of prior BCMA exposure on response and durability of response. Real-world experience with adverse events, particularly infections and ocular complications, was also discussed, as were the implications of these findings for treatment sequencing as BCMA-directed therapies move into earlier lines of therapy.

This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Marc-Andrea Bärtsch, Heidelberg University Hospital, DE, delivered a presentation on the current applications of BCMA-directed therapies in multiple myeloma (MM) and the evolving clinical landscape.

In this presentation, Bärtsch discussed the rationale for targeting BCMA in MM and reviewed pivotal clinical trial data supporting the approval of BCMA-directed therapies. Bärtsch outlined the mechanisms of action, clinical positioning, and key efficacy and safety findings for antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies, highlighting differences in availability, toxicity profiles, and durability of response across treatment modalities and lines of therapy.

This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

Hosted on Acast. See acast.com/privacy for more information.

The Multiple Myeloma Hub spoke with Mehmet Hakan Kocoglu, University of Maryland, Baltimore, US. We asked, What are the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM?

In this interview, Mehmet Hakan Kocoglu discussed the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM, focusing on the key efficacy and safety data for this allogeneic BCMA-directed CAR T-cell therapy.

This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen receptor (CAR) T-cell therapy for eligible patients with multiple myeloma. The meeting opened with a presentation by Sagar Lonial and featured a discussion including Morie Gertz, Elena Zamagni, Meral Beksaç, and Sonia Zweegmann.

During his presentation, Lonial provided an overview of approved and investigational CAR T-cell therapies for multiple myeloma, the CAR T-cell therapy treatment process, and multi-step treatment pathway. He explored barriers to treatment with CAR T-cell therapy, racial disparities in access to CAR T-cell therapy, and manufacturing and attrition considerations. He discussed potential strategies for improving access to CAR T-cell therapy for eligible patients, exploring patient selection and referral, optimizing the pre-CAR-T infusion process, use of CAR T-cell therapy in earlier lines of therapy, accelerated manufacturing, and allogeneic CAR T-cell therapies.

This discussion topic is supported by Kite through Gilead Sciences Europe Ltd, who provided funding. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.

Hosted on Acast. See acast.com/privacy for more information.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub was pleased to speak with Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked about the long-term PFS outcomes with ciltacabtagene autoleucel (cilta-cel) for standard-risk relapsed/refractory multiple myeloma (RRMM) from the CARTITUDE-4 trial.

In this interview, Costa first provided an overview of the phase III CARTITUDE-4 (NCT04181827) study design, explaining how the findings have impacted the treatment landscape for multiple myeloma. He then discussed the subgroup of patients in the trial with standard-risk cytogenetics, highlighting the high proportion who remain progression-free 30 months after receiving cilta-cel. He concluded by considering the potential impact of these findings, and the possibility that cilta-cel may offer a single-dose curative option for these patients.

This educational resource is independently supported by Legend Biotech. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about clinical experience with belantamab mafodotin, with a focus on strategies for managing ocular toxicity.

During this interview, Popat discussed clinical experience using belantamab mafodotin for patients with relapsed or refractory multiple myeloma (RRMM), highlighting its mechanism as a B-cell maturation antigen (BCMA)-directed antibody–drug conjugate and the practical management of associated ocular toxicities. Popat emphasized key considerations in patient selection, treatment sequencing, and individualized dosing strategies to optimize outcomes while minimizing adverse events. The discussion also covered real-world approaches to monitoring, dose adjustment, and maintaining long-term treatment benefit without compromising safety or efficacy.

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.